Skip to main content
Contact Us
Subscribe
E-Edition
72°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nanobiotix S.A. ADR
(NQ:
NBTX
)
7.230
-0.030 (-0.41%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Nanobiotix S.A. ADR
< Previous
1
2
3
4
Next >
NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 31, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3
August 15, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023
August 04, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix S.A. (NASDAQ: NBTX) Leading the Way in Monday Trading Based on Percentage Gain
July 10, 2023
Via
Investor Brand Network
Voting Rights and Shares Capital of the Company
July 20, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers
July 19, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3
July 10, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
June 08, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update
May 17, 2023
Reported €30.2 million in cash and cash equivalents as of March 31, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company
May 05, 2023
Company agreed to term sheet as of May 3, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results
April 24, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023
April 17, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
April 11, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call
March 27, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023
March 14, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
February 14, 2023
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
January 11, 2023
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer
December 27, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement
December 21, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
December 08, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 15, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer
November 14, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer
November 10, 2022
Data to be discussed during Nanobiotix Q3 Earnings Call at 8:00AM EST
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update
November 09, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Voting Rights and Shares Capital of the Company
November 08, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3
November 02, 2022
Multidisciplinary board includes twelve (12) experts from the United States and Europe that will support the development of lead therapeutic candidate NBTXR3
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Present at the Jefferies London Healthcare Conference
October 31, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Announce Third Quarter 2022 Financial Results on November 9, 2022
October 27, 2022
Conference Call and Webcast to be Held at 8:00 AM ET / 2:00 PM CET on November 10, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Executes Definitive Agreement to Restructure Existing Loan With the European Investment Bank
October 18, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix: Voting Rights and Shares Capital of the Company
October 10, 2022
From
Nanobiotix
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.